Combined with the administration’s erratic regulation and policymaking, it threatens to undo the salutary ecosystem that made ...

They aren't just "pandemic stocks." ...

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...

An early Moderna COVID‑19 trial has resurfaced six years on, amid ongoing debate over vaccine risks, guidance and public trust.

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma up to $2.25 billion to settle a ...

If you are wondering whether Moderna's share price really reflects what the business is worth today, you are not alone. That is exactly what this article will unpack. The stock recently closed at ...

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct ...

Yahoo Finance anchor Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute. US stock exchanges, in particular the NASDAQ (^IXIC, ^GSPC, ^DJI), climb following ...

Add Yahoo as a preferred source to see more of our stories on Google. Sarah Silbiger/Getty Images Moderna announced the Food and Drug Administration (FDA) will review its new mRNA flu vaccine, ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...